Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CLN-619 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Carcinoma; Cervical cancer; Endometrial cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Parotid cancer; Salivary gland cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Cullinan Therapeutics

    • Most Recent Events

    • 04 Jun 2024 According to Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology, Enrolment in both arms of the dose escalation was complete and based on the findings from dose escalation arms, expansion cohorts will be opened in endometrial cancer and NSCLC.
    • 04 Jun 2024 Results (data cutoff date: 24 Nov 2023) reporting safety and efficacy data presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 23 May 2024 According to Cullinan Oncology media release, company announced first clinical data from Findings from the clinical trial will be shared at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting as a poster presentation during the session on June 1, 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top